JP5095216B2 - アリールイミダゾールおよびその抗癌剤としての使用 - Google Patents

アリールイミダゾールおよびその抗癌剤としての使用 Download PDF

Info

Publication number
JP5095216B2
JP5095216B2 JP2006539065A JP2006539065A JP5095216B2 JP 5095216 B2 JP5095216 B2 JP 5095216B2 JP 2006539065 A JP2006539065 A JP 2006539065A JP 2006539065 A JP2006539065 A JP 2006539065A JP 5095216 B2 JP5095216 B2 JP 5095216B2
Authority
JP
Japan
Prior art keywords
substituted
aryl
heteroaryl
compound
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006539065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511504A5 (enExample
JP2007511504A (ja
Inventor
マリオ ヒュースカ
ラエド アル−カワスメ
エイピン エイチ ヤング
ヨーン リー
リサ ロック
Original Assignee
ローラス セラピューティクス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ローラス セラピューティクス インコーポレーテッド filed Critical ローラス セラピューティクス インコーポレーテッド
Publication of JP2007511504A publication Critical patent/JP2007511504A/ja
Publication of JP2007511504A5 publication Critical patent/JP2007511504A5/ja
Application granted granted Critical
Publication of JP5095216B2 publication Critical patent/JP5095216B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2006539065A 2003-11-14 2004-11-15 アリールイミダゾールおよびその抗癌剤としての使用 Expired - Fee Related JP5095216B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52027903P 2003-11-14 2003-11-14
US60/520,279 2003-11-14
US59950904P 2004-08-06 2004-08-06
US60/599,509 2004-08-06
PCT/IB2004/052433 WO2005047266A1 (en) 2003-11-14 2004-11-15 Aryl imidazoles and their use as anti-cancer agents

Publications (3)

Publication Number Publication Date
JP2007511504A JP2007511504A (ja) 2007-05-10
JP2007511504A5 JP2007511504A5 (enExample) 2007-12-27
JP5095216B2 true JP5095216B2 (ja) 2012-12-12

Family

ID=34594988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539065A Expired - Fee Related JP5095216B2 (ja) 2003-11-14 2004-11-15 アリールイミダゾールおよびその抗癌剤としての使用

Country Status (7)

Country Link
US (2) US8969372B2 (enExample)
EP (1) EP1692113B1 (enExample)
JP (1) JP5095216B2 (enExample)
AU (1) AU2004289539C1 (enExample)
CA (1) CA2545942C (enExample)
DK (1) DK1692113T3 (enExample)
WO (1) WO2005047266A1 (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2497116T3 (es) 2002-08-19 2014-09-22 Lorus Therapeutics Inc. Imidazoles 2,4,5-trisustituidos y su uso como agentes antimicrobianos
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US7442716B2 (en) * 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
JP5507049B2 (ja) 2004-12-30 2014-05-28 アステックス、セラピューティックス、リミテッド 医薬品
JP5334575B2 (ja) * 2005-05-25 2013-11-06 ローラス セラピューティクス インコーポレーテッド ２−インドリルイミダゾ［４，５‐ｄ］フェナントロリン派生物および癌治療におけるそれらの使用
EP1915374B1 (en) 2005-05-25 2014-04-02 Lorus Therapeutics Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
SG162803A1 (en) * 2005-06-27 2010-07-29 Exelixis Inc Imidazole based lxr modulators
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007124589A1 (en) * 2006-05-02 2007-11-08 Merck Frosst Canada Ltd. Methods for treating or preventing neoplasias
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
GB2462715B (en) * 2007-02-26 2011-08-03 Univ Yonsei Iacf Imidazole derivatives that induce apoptosis and their therapeutic uses
CN101130539B (zh) * 2007-09-26 2012-05-30 浙江大学 吲哚取代咪唑啉-2-酮类衍生物及其制备方法和用途
CN102015686B (zh) * 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010102393A1 (en) * 2009-03-12 2010-09-16 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d]phenanthroline derivatives and their use to inhibit angiogenesis
AU2010254082B2 (en) * 2009-05-28 2015-01-29 Exelixis, Inc. LXR modulators
ES2835553T3 (es) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN101735217B (zh) * 2009-12-15 2012-09-26 广东药学院 咪唑[4,5-f][1,10]菲咯啉及其衍生物在制备抗肿瘤药物中的应用
CN102821607B (zh) 2009-12-21 2014-12-17 萨穆梅德有限公司 1H-吡唑并[3，4-b]吡啶及其治疗应用
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CN103209981B (zh) * 2010-09-10 2016-12-28 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
HRP20190281T1 (hr) 2011-09-14 2019-05-31 Samumed, Llc Indazol-3-karboksamidi i njihova uporaba kao inhibitora signalizacijskog puta wnt/b-katenin
WO2013070996A1 (en) 2011-11-11 2013-05-16 Novartis Ag Method of treating a proliferative disease
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
PL2770994T3 (pl) 2012-05-04 2020-03-31 Samumed, Llc 1H-Pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
EP2943198B1 (en) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP2976342A4 (en) * 2013-03-20 2016-08-10 Aptose Biosciences Inc 2-SUBSTITUTED IMIDAZO [4,5-D] PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
US20150104392A1 (en) 2013-10-04 2015-04-16 Aptose Biosciences Inc. Compositions, biomarkers and their use in the treatment of cancer
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016086022A2 (en) * 2014-11-26 2016-06-02 Channel Therapeutics, Inc. Heteroaromatic imidazolyl compounds and methods for treating cancer
CA3030582A1 (en) * 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
KR20180080262A (ko) 2015-11-06 2018-07-11 사뮤메드, 엘엘씨 골관절염의 치료
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
ES2933109T3 (es) 2016-06-01 2023-02-02 Biosplice Therapeutics Inc Proceso para preparar N-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida
CN106220612A (zh) * 2016-08-10 2016-12-14 大连理工大学 一类含吲哚的菲并[9,10‑d]咪唑类衍生物及其合成和应用
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
CN110709082A (zh) 2016-10-21 2020-01-17 萨穆梅德有限公司 吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途
KR102558716B1 (ko) 2016-11-07 2023-07-21 사뮤메드, 엘엘씨 단일-투여량, 즉시-사용가능한 주사용 제제
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
KR102070879B1 (ko) * 2017-10-17 2020-01-29 성균관대학교산학협력단 Mnpⅱ를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CA3081261A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
CU24661B1 (es) 2018-01-17 2023-05-11 Aurigene Discovery Tech Ltd Compuestos de alquinileno sustituidos como agentes anticancerígenos
AU2020270303B2 (en) 2019-05-08 2023-09-07 Tyk Medicines, Inc. Compound used as kinase inhibitor and application thereof
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors
CN116554126B (zh) * 2023-04-18 2025-04-18 兰州大学 一种靶向降解cdk6的化合物及应用

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE585507A (enExample) * 1960-03-31
US3297710A (en) * 1963-04-09 1967-01-10 Du Pont Oxoarylidene-imidazoles
US3714181A (en) * 1970-12-31 1973-01-30 American Cyanamid Co 2-aryl-5,10-diphenylphenanthro(9,10-d)azoles
US4089747A (en) * 1976-08-09 1978-05-16 Eastman Kodak Company Compositions for the detection of hydrogen peroxide
US4535058A (en) 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
DE3141063A1 (de) 1981-10-13 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4423046A (en) * 1982-04-05 1983-12-27 Sterling Drug Inc. Antibacterial and antiprotozoal 1-methyl-5-nitro-2-(2-phenylvinyl)imidazoles
DE3422175A1 (de) 1984-06-04 1985-12-19 Julius Dr. 8000 München Kern Verfahren zur beimischung von ammoniak zu saure schadstoffe enthaltenden abgasen oder luft
WO1987003591A1 (fr) * 1985-12-12 1987-06-18 Ube Industries, Ltd. Nouveaux derives d'imidazole, bactericides les contenant et procede permettant leur preparation
JPS614960A (ja) 1984-06-19 1986-01-10 Fuji Photo Film Co Ltd 分析試薬および多層化学分析要素
US4762706A (en) 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US5443956A (en) 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US5081230A (en) 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US4720459A (en) 1985-02-14 1988-01-19 Medical College Of Wisconsin Research Foundation, Inc. Myelomas for producing human/human hybridomas
US4758421A (en) 1985-03-15 1988-07-19 The Board Of Trustees Of The Leland Stanford Junior University Bleomycin conjugates and method
IT1214597B (it) * 1985-04-15 1990-01-18 Rorer Italiana Spa Derivati dell'imidazolo adattivita' antimicotica, procedimento ed intermedi per laloro preparazione e composizioni che li contengono.
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5024935A (en) * 1987-12-18 1991-06-18 Eastman Kodak Company Dye-providing composition, diagnostic test kit and their use in method for ligand determination using peroxidase labeled-receptor
US5047318A (en) * 1988-06-13 1991-09-10 Eastman Kodak Company Imidazole leuco dye composition containing 4'-hydroxyacetanilide, diagnostic kit and method using same
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US5514550A (en) * 1989-02-03 1996-05-07 Johnson & Johnson Clinical Diagnostics, Inc. Nucleic acid test article and its use to detect a predetermined nucleic acid
US5441716A (en) 1989-03-08 1995-08-15 Rocky Research Method and apparatus for achieving high reaction rates
AU627295B2 (en) 1989-03-08 1992-08-20 Rocky Research Method and apparatus for achieving high reaction rates in solid-gas reactor systems
JPH02258017A (ja) 1989-03-31 1990-10-18 Babcock Hitachi Kk 固体還元剤を用いた排ガス脱硝装置
US4970226A (en) * 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5161389A (en) 1990-11-13 1992-11-10 Rocky Research Appliance for rapid sorption cooling and freezing
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ZA945363B (en) 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
US5496702A (en) * 1994-09-01 1996-03-05 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having stable leuco dye coatings
FI972492A0 (fi) 1994-12-13 1997-06-12 Hoffmann La Roche Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
TW424172B (en) * 1995-04-19 2001-03-01 Hitachi Chemical Co Ltd Photosensitive resin composition and photosensitive element using the same
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
WO1997036587A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. A method of treating cancer
US5693589A (en) * 1996-05-08 1997-12-02 Eastman Kodak Company Thermal imaging recording element
EP0812829A1 (en) * 1996-06-14 1997-12-17 Ontogen Corporation Substituted imidazoles as modulators of multi-drug resistance
IT240917Y1 (it) 1996-10-01 2001-04-11 Stefcom Spa Scarpa con tomaia avente porzione per la traspirazione dell'internodella scarpa
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
AU740425B2 (en) 1996-12-16 2001-11-01 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5809775A (en) 1997-04-02 1998-09-22 Clean Diesel Technologies, Inc. Reducing NOx emissions from an engine by selective catalytic reduction utilizing solid reagents
AU7138298A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
JPH10319584A (ja) * 1997-05-21 1998-12-04 Brother Ind Ltd マイクロカプセルを用いた感光性記録材料
DE19728343C5 (de) 1997-07-03 2013-02-21 Robert Bosch Gmbh Verfahren und Vorrichtung zur selektiven katalytischen NOx-Reduktion
CA2294898A1 (en) 1997-07-03 1999-01-14 Neurogen Corporation Certain diarylimidazole derivatives; a new class of npy specific ligands
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6329375B1 (en) * 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
GB9717804D0 (en) * 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
JPH11199582A (ja) 1998-01-05 1999-07-27 Sagami Chem Res Center ４（５）−（３−インドリル）イミダゾール誘導体
US5915891A (en) 1998-02-17 1999-06-29 Fridman; Yevgeny Z. Drill guide and method for installing a door lock
US6589966B1 (en) 1998-03-18 2003-07-08 Wake Forest University Health Sciences Cytotoxic metal chelators and methods for making and using same
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
AU2164300A (en) 1998-12-04 2000-06-26 N.V. Organon Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
JP2000273088A (ja) 1999-01-18 2000-10-03 Nippon Soda Co Ltd トリフェニルイミダゾール化合物および農園芸用殺菌剤
JP2000281588A (ja) 1999-03-30 2000-10-10 Sankyo Co Ltd ガンの予防又は治療薬及びそのスクリーニング方法
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
US7364868B2 (en) 1999-05-19 2008-04-29 The Uab Research Foundation Krüppel-like transcriptional factor KLF4/GKLF and uses thereof
DE19925631A1 (de) 1999-06-04 2000-12-07 Georg Gros Beschichtungsverfahren und Beschichtungsgemisch
WO2000078761A1 (en) * 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
US6266955B1 (en) 1999-08-20 2001-07-31 Caterpillar Inc. Diagnostic system for an emissions control on an engine
CN1087744C (zh) 1999-09-24 2002-07-17 中国科学院化学研究所 一种钌（ⅱ）多吡啶配合物及其制备方法
CN1088713C (zh) * 1999-09-24 2002-08-07 中国科学院化学研究所 用于二级pH传感的钌（Ⅱ）多吡啶配合物及其制备方法
AU782401B2 (en) * 1999-10-08 2005-07-28 Taiji Biomedical, Inc. Methods of enhancing chemotherapy
US7115645B2 (en) * 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
CA2404432A1 (en) 2000-03-27 2001-10-04 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
US7199137B2 (en) * 2000-09-21 2007-04-03 Smithkline Beecham Plc Imidazole derivatives as Raf kinase inhibitors
JP4162994B2 (ja) 2000-10-13 2008-10-08 ヴァイオン ファーマシューティカルズ， インコーポレイテッド 諸疾患状態の処置のための薬物に使用する化合物とその製造方法
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
WO2002072576A1 (en) * 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
JP2002275458A (ja) 2001-03-21 2002-09-25 Fukuoka Prefecture フォトクロミックアモルファス材料及び高密度光記録媒体
EP1432690A2 (en) * 2001-04-16 2004-06-30 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
US6916440B2 (en) 2001-05-31 2005-07-12 3M Innovative Properties Company Processes and apparatus for making transversely drawn films with substantially uniaxial character
JP3759882B2 (ja) 2001-06-01 2006-03-29 株式会社日立製作所 ポンプ装置
DE10134775A1 (de) 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US6852727B2 (en) * 2001-08-01 2005-02-08 Merck & Co., Inc. Benzimisazo[4,5-f]isoquinolinone derivatives
CA2464000C (en) * 2001-10-19 2011-04-19 Ortho-Mcneil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
AU2003215112A1 (en) * 2002-02-07 2003-09-02 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
KR100653662B1 (ko) 2002-06-19 2006-12-05 쿠리타 고교 가부시키가이샤 수소 저장 방법, 수소 포접 화합물 및 그 제조 방법
EP1532118A2 (en) 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
ES2497116T3 (es) * 2002-08-19 2014-09-22 Lorus Therapeutics Inc. Imidazoles 2,4,5-trisustituidos y su uso como agentes antimicrobianos
DE10251472A1 (de) 2002-11-06 2004-05-19 Robert Bosch Gmbh Verfahren zur Nachbehandlung von Abgasen und Anordnung hierzu
WO2004071464A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
CA2425797C (en) * 2003-04-17 2013-10-15 Xerox Corporation Organic light emitting devices
US7989089B2 (en) * 2003-04-17 2011-08-02 Lg Display Co., Ltd. Organic luminescent compounds and methods of making and using same
DE10323591A1 (de) 2003-05-16 2004-12-02 E.G.O. Elektro-Gerätebau GmbH Verfahren und Vorrichtung zur Erzeugung eines Gases aus einem Sublimationsgut
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
US20050195793A1 (en) 2004-03-05 2005-09-08 Lockheed Martin Corporation System for locally synchronizing a group of mobile devices
US20050282285A1 (en) 2004-06-21 2005-12-22 Eaton Corporation Strategy for controlling NOx emissions and ammonia slip in an SCR system using a nonselective NOx/NH3
US20090280047A1 (en) 2004-08-03 2009-11-12 Claus Hviid Christensen Solid ammonia storage and delivery material
EP1868941B9 (en) 2005-02-03 2017-02-15 Amminex Emissions Technology A/S High density storage of ammonia
EP1915374B1 (en) * 2005-05-25 2014-04-02 Lorus Therapeutics Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
JP2008546968A (ja) 2005-06-29 2008-12-25 アムミネクス・アー／エス 固体アンモニア貯蔵媒体からのアンモニアの安全な制御された送出のための方法および装置
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
LT3207941T (lt) 2006-09-07 2020-04-10 Scott & White Memorial Hospital Būdai ir kompozicijos difterijos toksino ir interleukino 3 konjugatų pagrindu
WO2008125883A1 (en) 2007-04-16 2008-10-23 Cancer Research Technology Limited Cancer markers for prognosis and screening of anti-cancer agents
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP2011505336A (ja) 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
WO2009151503A2 (en) 2008-04-10 2009-12-17 University Of Florida Research Foundation, Inc. Compositions and methods for the treatment of a neoplasia
JP5340265B2 (ja) 2008-06-27 2013-11-13 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010102393A1 (en) 2009-03-12 2010-09-16 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d]phenanthroline derivatives and their use to inhibit angiogenesis
EP2239580B1 (en) 2009-04-09 2013-03-27 Lga Biotecnologie Srl Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis
WO2010117057A1 (ja) 2009-04-10 2010-10-14 協和発酵キリン株式会社 抗tim-3抗体を用いた血液腫瘍治療法
EP2491116A4 (en) 2009-10-22 2013-12-11 Univ Jefferson CELL-BASED ANTI-CANCER COMPOSITIONS AND METHODS OF MAKING AND USING SAME
US8524240B2 (en) 2009-10-26 2013-09-03 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
US20130011411A1 (en) 2010-01-06 2013-01-10 Pestell Richard G Methods and compositions for the diagnosis, prognosis, and treatment of cancer
KR101317513B1 (ko) 2010-05-17 2013-10-15 가톨릭대학교 산학협력단 대장암 또는 난소암 진단용 조성물, 진단키트 및 진단방법
MX2012014416A (es) 2010-06-28 2013-02-27 Threshold Pharmaceuticals Inc Tratamiento de cancer de sangre.
US20120172244A1 (en) 2010-12-20 2012-07-05 Steven Buechler Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
AU2012347460B2 (en) 2011-12-09 2017-05-25 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
TW201343920A (zh) 2012-03-29 2013-11-01 Nat Health Research Institutes 預測前列腺癌預後之分子標記、方法與套組
US20150104392A1 (en) 2013-10-04 2015-04-16 Aptose Biosciences Inc. Compositions, biomarkers and their use in the treatment of cancer

Also Published As

Publication number Publication date
CA2545942C (en) 2012-07-10
DK1692113T3 (en) 2018-01-08
US8969372B2 (en) 2015-03-03
EP1692113B1 (en) 2017-09-27
WO2005047266A9 (en) 2008-04-17
US20150374669A1 (en) 2015-12-31
WO2005047266A1 (en) 2005-05-26
US20070123553A1 (en) 2007-05-31
AU2004289539C1 (en) 2012-06-07
AU2004289539B2 (en) 2011-11-24
CA2545942A1 (en) 2005-05-26
EP1692113A1 (en) 2006-08-23
US20080262015A9 (en) 2008-10-23
JP2007511504A (ja) 2007-05-10
US10080739B2 (en) 2018-09-25
AU2004289539A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
JP5095216B2 (ja) アリールイミダゾールおよびその抗癌剤としての使用
CN1642542B (zh) 血管新生抑制剂
Chen et al. Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation
EA015779B1 (ru) Соединения для ингибирования митоза
CN101248072B (zh) 2-吲哚基咪唑并[4,5-d]菲咯啉衍生物及其在癌症治疗中的用途
JP2008514726A (ja) ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
JP2018514557A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
AU2007252982B2 (en) Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives
Wang et al. Synthesis, biological evaluation and molecular docking of thiazole hydrazone derivatives grafted with indole as novel tubulin polymerization inhibitors
WO2018068665A1 (zh) 微管蛋白抑制剂
KR102189562B1 (ko) 아실-하이드라존 및 옥사디아졸 화합물, 이를 포함하는 약학 조성물 및 이의 용도
JP6239103B2 (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
CN103429586A (zh) 哌嗪二酮化合物
JP5334575B2 (ja) ２−インドリルイミダゾ［４，５‐ｄ］フェナントロリン派生物および癌治療におけるそれらの使用
EP2909171B1 (fr) Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer
Wang et al. Design, synthesis, and biological evaluation of Flavokavain B derivatives as potent TRF2 inhibitors for the treatment of Osteosarcoma
JP2005525999A (ja) 原発性脳腫瘍または転移性脳腫瘍を治療または予防するためのベンゾピラノン誘導体の使用
JP2016516082A (ja) ２−置換イミダゾ［４，５−ｄ］フェナントロリン誘導体及び癌の治療におけるそれらの使用
HK1094798B (en) Aryl imidazoles and their use as anti-cancer agents
HK1094798A (en) Aryl imidazoles and their use as anti-cancer agents
KR20100004681A (ko) ｐ21의 발현을 증가시키는 활성을 갖는 화합물5,4'-디메톡시플라본의 항암제로서의 용도
ITNA20090047A1 (it) Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071212

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120919

R150 Certificate of patent or registration of utility model

Ref document number: 5095216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150928

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees